An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation from Drimia maritima (L.) Stearn): A Pilot Randomized Triple-Blinded Placebo-Controlled Clinical Trial

Table 3

Comparison of the mean distance in the 6MWT and O₂ saturation between Squill-Oxymel and placebo groups.

Variables	Group	Before M ± SD	After M ± SD	Wilcoxon signed-rank test
Distance in the 6MWT	Squill-Oxymel; Placebo	369.76 ± 117.26; 410.00 ± 133.33	387.38 ± 123.53; 399.81 ± 106.40	0.011; 0.198
O2 saturation at start of the 6MWT	Squill-Oxymel Placebo	86.90 ± 8.64; 89.95 ± 5.40	85.19 ± 11.25; 88.90 ± 6.56	0.75; 0.59
O2 saturation at end of the 6MWT	Squill-Oxymel Placebo	77.00 ± 13.28; 85.57 ± 9.10	77.86 ± 12.52; 81.29 ± 10.32	0.37; 0.003

M ± SD: mean ± standard deviation.